Market Overview

A RNA polymerase (RNAP), also known as ribonucleic acid polymerase, is a multi-subunit enzyme that catalyzes the process of transcription where an RNA polymer is synthesized from a DNA template. Any dysregulation in the normal functioning of the enzyme can lead to many disorders such as breast cancer, ovarian cancer, lung cancer and others.

RNA polymerase inhibitors is a substance that blocks enzyme RNA polymerase in the cell. Blocking of RNA polymerase helps the cancer cells in repairing their damaged part of DNA. The global RNA polymerase inhibits market is likely to grow with the increasing prevalence of cancer. After cardiovascular diseases, cancer is the leading cause of death across the world. World Health Organization (WHO) states that cancer causes around 8.3 million deaths every year and is expected to increase further

The outbreak of novel coronavirus has caused a disturbance in almost all the industries. The coronavirus pandemic has also affected the RNA polymerase inhibitors market. Since coronavirus has become the main focus, many biotech and pharmaceutical companies are engaged in developing coronavirus vaccine, this is hampering the research and development activity of RNA polymerase inhibitors.

Due to the coronavirus, the flow of patients into the hospitals has been reduced which has led to decline in the number of treatments. There has been a disruption in the supply of various API’s used in making the RNA polymerase inhibitors which is hampering the production of RNA polymerase inhibitors.

The increasing prevalence of cancer is the major factor driving the growth of the global RNA polymerase inhibitors market. The high diagnostic rate is considered as the another key driver of the global RNA polymerase inhibitors market.

Furthermore, the rising geriatric population and advancements in the global health care sector is expected to drive the global RNA polymerase inhibitors market. Furthermore, the existing market players are adopting advanced techniques for the development of scientifically advanced treatments for cancer, this is likely to propel the demand for RNA polymerase inhibitors during the forecast period.

However, stringent government regulations and high cost of treatment are expected to restrain the global RNA polymerase inhibitors market over the forecast period.

RNA polymerase inhibitors market has been segmented on the basis of drug type, application, and distribution channel.

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Get FREE Report Sample

Segmentation

drug type	Lynparza Veliparib Rucaparib Talazoparib Niraparib Others
Based on the indication	Ovarian Cancer Breast Cancer Lung Cancer Prostate Cancer Pancreatic Cancer
distribution channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies

Based on the drug type, lynparza segment is expected to hold a major share in the RNA polymerase inhibitors market due to its effectiveness as compared to other RNA polymerase inhibitors in the market. Based on the application, breast cancer segment is expected to dominate the RNA polymerase inhibitors market due to its higher prevalence rate than any other cancer.

Breast cancer is expected to be followed by ovarian cancer. Based on the distribution channel, the hospital pharmacies are expected to be the most profitable segment in the global RNA polymerase inhibitors market due to the advanced medical facilities and larger number of patients flow in the hospitals.

North America is expected to dominate the global RNA polymerase inhibitors market due to the rising prevalence of cancer and continuous research and development activities in the region. Europe is expected to grow at a significant rate in the global RNA polymerase inhibitors market during the forecast period due to the well-established healthcare system and diagnostic advancements in the region.

Asia-Pacific is expected to grow at a faster rate due to the rising healthcare spending and various initiatives by the government. Middle east and Africa is expected to show a slowest growth rate in the global RNA polymerase inhibitors market due less advanced medical facilities in the region.

The key participants operating in the global RNA polymerase inhibitors market are: Johnson & Johnson, AstraZeneca Plc., AbbVie Inc., Bristol Myers Squibb, Repare Therapeutics Inc., Merck & Co., Inc., Genentech, Inc., Artios Pharma, Pfizer, Inc., Sierra Oncology, Inc., GlaxoSmithKline Plc., Clovis Oncology Inc., Karyopharm Therapeutics Inc., and others.